Document Type : Original Article
Authors
- pejman porouhan 1
- Reza Yousefabadi 2
- Alaleh Abbaspour 2
- Babak PeyroShabany 3
- Danial Fazilat-Panah 4
- Ahmad Foroughi 5
- Seyed Alireza Javadinia 6
1 Assistant Professor, Department of Radiation Oncology, Vasee Hospital, Sabzevar University of Medical Sciences, Sabzevar, Iran
2 General Practitioner, Student Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran
3 Assistant Professor, Department of Internal Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran
4 Assistant Professor, Cancer Research Center, Babol University of Medical Sciences, Babol, Iran
5 Student Research Committee, Iran University of Medical Sciences, Tehran, Iran
6 Assistant Professor, Non-Communicable Diseases Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
Abstract
Background: To investigate the survival of patients with brain metastases (BM) in Sabzevar.
Materials and Methods: In this retrospective cross-sectional study at two oncologic centers in Sabzevar, patients with BM either at the presentation or at during the follow-up were enrolled. Patients' documents were reviewed in terms of clinical and pathological features of the primary tumor, first-line treatments and treatments at the time of BM diagnosis and finally overall survival (OS) and BM-related survival rates. The data was entered into SPSS version 26 software and analyzed at a significance level of P<0.05.
Results: Eighty-four patients were enrolled (58.33% female, median age 57 [25-83]). Most frequent primary cancers were lung (non-small cell, 38.1%) and breast (34.52%). BM at the diagnosis of primary tumor was presented in 29 patients (34.5%). 61.9% had ≥5 BM, 97.6% were symptomatic, 80% had extracranial metastases (ECM). Headache (22.6%) and focal neurologic deficit (21.4%) were the most frequent reported symptoms. Primary BM treatments were: Surgery 6.1%; SRT 0%; whole brain radiotherapy (WBRT) 87.8%, systemic treatments 6.1%; best supportive care (BSC) 0%. Median OS after BM diagnosis for all was 5 months (surgery: 11, systemic: 3, WBRT: 5). In patients treated with WBRT, 64.8% had ≥5 BM, 83.3% ECM, 16.9% were ≥70 years.
Conclusion: Survival of patients with BM is extremely poor. WBRT is the main treatment option. Patients who can tolerate the surgery may survive more.
Keywords
Main Subjects
- Counsell CE, Collie DA, Grant R. Incidence of intracranial tumours in the Lothian region of Scotland, 1989-90. J Neurol Neurosurg Psychiatry. 1996;61(2):143-50. doi:10.1136/jnnp.61.2.143. [PubMed:8708681].
- Fogelholm R, Uutela T, Murros K. Epidemiology of central nervous system neoplasms. A regional survey in Central Finland. Acta Neurol Scand. 1984;69(3):129-36. doi:10.1111/j.1600-0404.1984.tb07791.x. [PubMed:6609517].
- Materljan E, Materljan B, Sepcić J, Tuskan-Mohar L, Zamolo G, Erman-Baldini I. Epidemiology of central nervous system tumors in Labin area, Croatia, 1974-2001. Croat Med J. 2004;45(2):206-12. [PubMed:15103760].
- Smedby KE, Brandt L, Bäcklund ML, Blomqvist P. Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer. 2009;101(11):1919-24. doi:10.1038/sj.bjc.6605373. [PubMed:19826419].
- Walker AE, Robins M, Weinfeld FD. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology. 1985;35(2):219-26. doi:10.1212/wnl.35.2.219. [PubMed:3969210].
- Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G. Epidemiology of metastatic brain tumors. Neurosurg Clin N Am. 2011;22(1):1-6, v. doi:10.1016/j.nec.2010.08.007. [PubMed:21109143].
- Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48-54. doi:10.1007/s11912-011-0203-y. [PubMed:22012633].
- Fabi A, Felici A, Metro G, Mirri A, Bria E, Telera S, et al. Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. J Exp Clin Cancer Res. 2011;30(1):10. doi:10.1186/1756-9966-30-10. [PubMed:21244695].
- Steindl A, Yadavalli S, Gruber K-A, Seiwald M, Gatterbauer B, Dieckmann K, et al. Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non–small cell lung cancer brain metastases. Cancer. 2020;126(19):4341-52. doi:https://doi.org/10.1002/cncr.33085.
- Sacks P, Rahman M. Epidemiology of Brain Metastases. Neurosurgery Clinics of North America. 2020;31(4):481-8. doi:https://doi.org/10.1016/j.nec.2020.06.001.
- Lamba N, Kearney RB, Catalano PJ, Hassett MJ, Wen PY, Haas-Kogan DA, et al. Population-based estimates of survival among elderly patients with brain metastases. Neuro Oncol. 2021;23(4):661-76. doi:10.1093/neuonc/noaa233. [PubMed:33068418].
- Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511-21. doi:10.1093/neuonc/nox077. [PubMed:28444227].
- Aizer AA, Lamba N, Ahluwalia MS, Aldape K, Boire A, Brastianos PK, et al. Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro-Oncology. 2022;24(10):1613-46. doi:10.1093/neuonc/noac118.
- Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494-500. doi:10.1056/nejm199002223220802. [PubMed:2405271].
- Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665-72. doi:10.1016/s0140-6736(04)16250-8. [PubMed:15158627].
- Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018;379(8):722-30. doi:10.1056/NEJMoa1805453. [PubMed:30134131].
- Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113-25. doi:10.1056/NEJMoa1713137. [PubMed:29151359].
- Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015;5(11):1164-77. doi:10.1158/2159-8290.Cd-15-0369. [PubMed:26410082].
- Zakrzewski J, Geraghty LN, Rose AE, Christos PJ, Mazumdar M, Polsky D, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer. 2011;117(8):1711-20. doi:10.1002/cncr.25643. [PubMed:21472718].
- Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast. 2006;15(2):219-25. doi:10.1016/j.breast.2005.04.017. [PubMed:16026983].
- Witzel I, Laakmann E, Weide R, Neunhöffer T, Park-Simon TJ, Schmidt M, et al. Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. Eur J Cancer. 2018;102:1-9. doi:10.1016/j.ejca.2018.07.004. [PubMed:30099223].
- Yri OE, Astrup GL, Karlsson AT, Paulsen Ø, Van Helvoirt R, Lund JÅ, et al. 282MO Brain metastases: Real-life treatment patterns, survival and patient-reported outcomes – Results from a population-based, prospective study in 914 patients. Annals of Oncology. 2022;33:S668. doi:10.1016/j.annonc.2022.07.416.
- Gao HX, Huang SG, Du JF, Zhang XC, Jiang N, Kang WX, et al. Comparison of Prognostic Indices in NSCLC Patients with Brain Metastases after Radiosurgery. Int J Biol Sci. 2018;14(14):2065-72. doi:10.7150/ijbs.28608. [PubMed:30585269].
- Rades D, Bartscht T, Schild SE. Predictors of survival in patients with brain metastases from gastric cancer. Neoplasma. 2017;64(1):136-9. doi:10.4149/neo_2017_117. [PubMed:27881015].
- Rades D, Dziggel L, Manig L, Janssen S, Khoa MT, Duong VN, et al. Predicting Survival After Whole-brain Irradiation for Cerebral Metastases in Patients with Cancer of the Bladder. In Vivo. 2018;32(3):633-6. doi:10.21873/invivo.11285. [PubMed:29695570].
- Owonikoko TK, Arbiser J, Zelnak A, Shu HK, Shim H, Robin AM, et al. Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol. 2014;11(4):203-22. doi:10.1038/nrclinonc.2014.25. [PubMed:24569448].
- AlTamimi JO, AlJohani HA, Naaman N, Johar RA, Allam TA, Lary DAI. Brain Metastases in Adults: A Five-Year Observational Study From King Abdulaziz Medical City. Cureus. 2022;14(11):e31197. doi:10.7759/cureus.31197. [PubMed:36505114].
- Doğan A, Durmaz MO, Gezgin İ, Kaplan A. Surgical Management and Postoperative Outcome in patients with Brain Metastases: Our Surgical Experience. Journal of Nervous System Surgery. 2022;8(2):51-9. doi:10.54306/SSCD.2022.209.
- Ramos A, Giantini-Larsen A, Pannullo SC, Brandmaier A, Knisely J, Magge R, et al. A multidisciplinary management algorithm for brain metastases. Neurooncol Adv. 2022;4(1):vdac176. doi:10.1093/noajnl/vdac176. [PubMed:36532509].
)